This trend is well supported in similar mouse models of AD, with Tg mice treated with CRF1 antagonists (Antalarmin, R121919) demonstrating lower levels of Aβ, tau, and CORT (Dong et al., 2014; Campbell et al., 2015; Zhang Y. L. et al., 2016; Zhang and Rissman, 2017). Here, MAPT is linked to Alzheimer disease.